News

Local Professor Discusses Morehouse School Of Medicine’s Coronavirus-Related Clinical Trials

The first patient enrolled in Pfizer's COVID-19 vaccine clinical trial at the University of Maryland School of Medicine in Baltimore receives an injection in May.
The first patient enrolled in Pfizer's COVID-19 vaccine clinical trial at the University of Maryland School of Medicine in Baltimore receives an injection in May.
Credit University of Maryland School of Medicine via AP

As the push continues to create a vaccination for COVID-19, Morehouse School of Medicine (MSM) is conducting two novel coronavirus-related clinical trials.

As MSM’s clinical trials are happening locally, Pfizer and Moderna recently announced promising results from their Phase 3 trials. According to Pfizer, their vaccine appears to be more than 90% effective and Moderna’s vaccine appears to be 94.5% effective.

Lilly Immergluck, an associate professor of microbiology, biochemistry, immunology and pediatrics and the director of the Pediatric Clinical & Translational Research Unit, Clinical Research Center, joined Monday’s edition of “Closer Look.”

Immergluck talked with show host Rose Scott about combating the global health crisis, COVID-19 testing and the phases of MSM’s clinical trials.

 To listen to the full conversation, click the audio player above.

Guest:

  • Lilly Immergluck, an associate professor of microbiology, biochemistry, immunology & pediatrics and the director of the Pediatric Clinical & Translational Research Unit, Clinical Research Center